Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Multiple Myeloma (MM), Smoldering Multiple Myeloma (SMM), MGUS. Basic parameters: from 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Study on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics features, to effectively distinguish myeloma patients from healthy individuals.
Primary outcome measures
- Sensitivity and Specificity [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Age over 40 years.
- Diagnosed with MM, SMM, or MGUS through standard diagnostic procedures.
- Voluntarily participating and signed written informed consent.
Exclusion criteria
- Pregnant or lactating women.
- Prior cancer diagnosis within the past 5 years, or history of any form of systemic cancer therapy (including chemotherapy, targeted therapy, immunotherapy, etc.).
- History of organ transplantation, or allogeneic bone marrow or stem cell transplantation.
- History of blood transfusion within 7 days prior to blood collection.
- Poor compliance or potential interference with signing informed consent as judged by the investigator, or any other conditions rendering the subject unsuitable for the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07684274 · 2026-SR-462